|Articles|September 11, 2020

Study Finds Limits to sCR Compared With MRD in Tracking MM Response

A new study suggests stringent complete response is less meaningful than minimal residual disease status when evaluating patients with multiple myeloma.

Minimal residual disease (MRD) is a more valuable tool than stringent complete response (sCR) when it comes to measuring disease response and prognosis in patients with multiple myeloma (MM), according to a new study.

The International Myeloma Working Group has established 4 categories of deep response to treatment for MM. sCR was first developed in 2006. It includes normalization of the kappa and lambda serum free light chain (sFLC) ratio plus the absence of clonal plasma cells in bone marrow as measured by immunohistochemistry (IHC) or immunofluorescence with a sensitivity of 10-3.

Internal server error